Newsbenzinga
Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise
· Published
Article summary
Sagimet reports positive 52-week Phase 3 trial data for denifanstat in acne patients and prices a $115 million stock offering.
An excerpt from the original article.
Comments —
Loading comments…